Madrigal Pharma (MDGL) Tops Q4 EPS by $1.77, Beats on Revenue

Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($2.71), $1.77 better than the analyst estimate of ($4.48). Revenue for the quarter came in at $103.32 million versus the consensus estimate of $87.7 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
• Morgan Stanley Downgrades Sims Metal Management Ltd. (SGM:AU) (SMUPF) to Underweight